DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD], ulcerative colitis [UC], or indeterminate colitis [IC]) treated with originator infliximab (REM) and/or other medical therapies for IBD as part of routine clinical care. DEVELOP started in May 2007, is ongoing and has sites in the United States, Canada and in the EU (Belgium, Denmark, France, Germany, Italy, the Netherlands, and the United Kingdom).